FDA approves Genzyme plant for Fabrazyme manufacture

Published: 24-Jan-2012
Regulatory

Return to normal supply will start in the first quarter


The US FDA has approved Genzyme’s manufacturing plant in Framingham, Massachusetts, US for the production of Fabrazyme (agalsidase beta), a treatment for Fabry disease.

This follows the announcement last week that the European Medicines Agency has approved the plant.

The FDA approval allows Genzyme to begin the process of returning patients to full dosing (1mg/kg) levels.

The company says all patients in the US currently on the drug will return to full dosing in March.

The company will also begin to transition new patients in the US onto Fabrazyme at full dosing levels.

Following the EMA approval, Genzyme will begin the process of moving the most severely affected patients in Europe to full dose of Fabrazyme in the first quarter.

Globally, the complete return to normal supply levels of Fabrazyme will begin in the second quarter and continue throughout the year as planned.

  • Companies:
  • Genzyme
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

New NCEs focus on cancer and orphan diseases

Read more
The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

New NCEs focus on cancer and orphan diseases

The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Meeting regulatory expectations

Best practice and meeting the expectations of regulators on the use of plant isolates, bioburden strategies, rapid ID methods, auditing environmental controls and deviation management are topics taxing microbiologists. Susan Birks reports on issues discussed at the Pharmig conference
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Regulatory

A lucrative niche in orphan diseases?

The number of potential blockbuster drugs is in decline so many Big Pharma companies are looking to rare diseases to fill their pipelines because low sales volumes can be balanced out by premium prices.
Regulatory

EMA approves Genzyme plant for Fabrazyme production

Complete return to normal supply levels will not be immediate
Regulatory

Gaucher disease – eliglustat tartrate

Patients with Gaucher disease have a deficiency of the enzyme β-glucocerebrosidase, which means that glucosylceramide will accumulate in the lysosomes of their cells
Regulatory

Genzyme receives positive opinion for European approval of Renvela for patients with kidney disease

<p>The European Medicines Agency\'s Committee for Human Medicinal Products (CHMP) has adopted a positive opinion for the marketing authorisation of the phosphate binder Renvela (sevelamer carbonate) for use in patients with chronic kidney disease (CKD).</p>
Subscribe now